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ABSTRACT 
Cancer is one of the most common causes of death in the western world. Cancer is an 
umbrella term for over 100 different diseases all caused by mutations in cells leading to 
uncontrolled cell division and metastasis. The control of the cell division is extremely 
important in order to maintain homeostasis and avoid development of cancer. The cells 
in the body have to communicate with each other to keep homeostasis. This can 
subsequently regulate the cell cycle that controls cell division. Many proteins are involved 
in the control mechanisms to pass the cell through the cycle where phosphorylation and 
dephosphorylation are important mechanism for regulation. The cell division is also 
controlled by tumor suppressors that sense, for example, DNA damage or cell stress, to 
ascertain reediness for cell division and to minimize the amount of mutations. Two 
important proteins in the cell signaling are Protein Phosphatase 2A that act as switch for 
the pocket proteins that control the cell cycle, and p53 which is labeled “the guardian of 
the genome”, both are tumor suppressor. 
Protein Phosphatase 2A (PP2A), is together with PP1 responsible for 90% of all 
dephosphorylation events in the cell. Apart from controlling the cell cycle PP2A is 
involved in many other pathways making it a very important protein in cell signaling. 
Understanding its structure and function is crucial for understanding how it works at the 
molecular level and how difference cancer mutations are affecting its mechanism of 
action. PP2A consists of three subunits, a scaffolding (A), a catalytic (C) and a regulatory 
(B) for substrate recognition. In this thesis the structure and biochemical function of one 
of the regulatory subunits, B’’/PR70, is presented, a subunit who’s structure was 
unknown before the start of the doctoral project. A high-resolution structure of the core 
revealed 8 EF-hands where two were binding calcium. A mapping of the A-B’’ 
interaction is also presented. 
p53 is a common tumor suppressor that is mutated in 50% of all cancer tumors. It is 
involved in key decisions for cell cycle progression and apoptosis and more detailed 
understanding of this protein could shed light on the role of different p53 mutations in 
cancer. P53 is acting as a transcription factor and has a DNA binding core domain that 
binds to a response element on the target gene. In this thesis, a novel method to study 
biochemical events in cells and cell extract is applied for the first time on p53, the Cellular 
Thermal Shift Assay (CETSA). It is shown that p53-DNA can indeed be studied using 
this strategy and that binding profiles to four different oligonucleotides representing 
target genes with response elements, give distinct profiles for each mutation. This suggest 
that the CETSA strategy allows for more detailed functional studies of p53 in cells and 
that oligonucleotide profiling might constitute a novel mean to profile cancer patient cells 
for differential p53 activity.  
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1 INTRODUCTION 
About two billion years ago, eukaryotic cells appeared on earth. They have a nucleus 
containing all genetic information in chromosomes in contrast to prokaryotes that lack a 
nucleus. Eukaryotes can either be unicellular like amoebas and yeast, or multicellular like 
animals and humans. The human body consists of a huge number of cells, on average 
about one billion cells per gram of tissue. The cells exist in different forms in different 
tissues and organs. All these cells need to communicate with each other in order for the 
body to function properly and to maintain homeostasis. 
Communication between cells is called cell signaling, and is a complex system to govern 
basic cellular activities and coordinate all cell actions. The communication occurs as 
primarily chemical signals, which includes neurotransmitters, hormones or growth 
factors. A cell releases a signal that reaches a target cell, the receptors on the target cell 
surface react to the signals and convert the external signals to internal signaling 
transduction pathways. An example of pathways are the MAPK signaling pathway, which 
is a phosphorylation cascade pathway that function to control cell proliferation and 
apoptosis, another example is Wnt signaling that is regulating development of cell 
proliferation [1]. 
Eukaryotic cells multiply by division. The cell cycle is divided in several stages or phases 
(figure 1) [2]. The cell is resting in G0 phase, it is quiescent i.e. out of cycle. When the cell 
is stimulated by growth factors or mitotic signals it moves into G1 phase, starts to grow 
and at a certain stage enters the S phase where DNA synthesis takes place, the whole 
genome is copied. Before the cell goes into S phase it passes a restriction point (R-point) 
controlled by the “pocket-protein” retinoblastoma (Rb) protein [3]. Rb is bound to a 
transcription protein called E2F, inhibiting transcription of genes regulating the S-phase 
entry, when Rb becomes phosphorylated it releases E2F and allows the genes to be 
transcribed. In gap 2 (G2) the DNA is controlled for completion and correct replication. 
Subsequently the cell starts to prepare for division, mitosis (M), where the cell is divided 
into two daughter cells with one set of chromosome pairs in each cell. The daughter cells 
have the same setup of DNA. The cell cycle then starts all over again with G1 or goes 
into G0 for rest. The cell cycle is regulated by cyclins and cyclin-dependent kinases 
(CDKs). There are a number of different cyclins involved in the cell regulation, the levels 
of the different cyclins are increased and decreased during the phases of the cell cycle. 
The cyclins are the regulatory unit of the CDKs that phosphorylates protein substrates to 
move the cell through the phases by activating DNA synthesis, and to form structural 
components needed for mitosis. For example CDK4/6 phosphorylates Rb for the release 
of E2F [4]. 
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Figure 1. The cell cycle is divided in five phases. G0 the quiescence or rest phase. G1 were the cell starts to 
prepare for division, S phase with DNA replication, G2, and mitosis (M) when the cell is dividing. A 
restriction point (R-point) for control before entering the S phase. Cyclins and CDKs are regulators of the 
cell cycle. 
When cells are no longer needed, they kill themselves with an intracellular death program 
known as programmed cell death or more commonly called apoptosis. Apoptosis also 
occur when the DNA get damaged by for example stress, UV-radiation or environmental 
chemicals. In order to protect the cell from mutations and diseases that could emerge 
from DNA damage, a signaling pathway starts in order to activate proteins that kill the 
cell. Apoptosis is therefore crucial for the multicellular organism to remove damaged 
cells. When DNA is damaged, p21, an inhibitor of CDK, is upregulated and stop the 
progression into S phase allowing the DNA to be repaired. If the DNA is severely 
damaged the tumor suppressor p53 activates pro-apoptotic proteins such as PUMA and 
BAX [5, 6] and the cell commits suicide instead of entering S phase. 
When the cell fails to control the cell cycle and to initiate cell cycle arrest or apoptosis in 
response to cell damage, it leads to diseases, in many cases cancer. Cancer is the most 
common cause of death for people under 85 years-old in Sweden, and the number of 
cases are increasing [7]. Among women the most common form of cancer is breast 
cancer and for men prostate cancer. A third of all people will be diagnosed with cancer, 
but the survival rates are relatively high and improving.  
Cancer is an umbrella term for over 100 different diseases involving abnormal cell 
growth with aggressive cells spreading to other parts of the body caused by metastasis [8]. 
Errors in the coordination of the cell cycle control lead to chromosomal alterations 
where genes are lost, rearranged or distributed unequally between the daughter cells, 
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leading to uncontrolled cell growth and tumorigenesis. Some tumors progress to cancer 
tumors by starting to spread their abnormal cells to other organs. 
Improved cancer therapies are urgently needed. Many traditional ones are hitting a broad 
range of cells, both cancer and healthy cells. There are new therapies with drugs that 
directly target proteins which are more specifically activated in cancer cells, and therefore 
lead to less toxicity in normal cells. Although promising, drug resistance often develop 
rapidly to these and other therapies, and establishing concepts for drugs which can 
overcome resistance development, is a major challenge in cancer research. More detailed 
knowledge about how the cell works and how signaling and metabolic pathways are 
coordinated in cancer cells are needed to accomplish this. New concepts to screen for 
drug targets and drugs to find such therapies for specific types of cancers are also needed. 
In this thesis two tumor suppressors, important for cell proliferation, are studied Protein 
Phosphatase 2A (PP2A) and p53. Structural and functional studies of PP2A shed light on 
its mechanism of regulation at the molecular level and studies of p53 provide a novel 
strategy to read out biochemical characteristics of this protein that might report on its 
activation state with implications for cancer therapy.  
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2 PROTEIN METHODOLOGIES 
2.1 PROTEIN EXPRESSION AND PURIFICATION  
To produce recombinant proteins, a host is needed to express the protein of interest in 
sufficient amount and in a well-folded and stable form. There are a range of different 
expression hosts available in both eukaryotic and prokaryotic cells. In the present work 
primarily E. coli has been used which is particularly useful for structural biology 
application, when it allows for rapid studies of many different expression constructs and 
conditions. One of the most commonly used E. coli systems is based on the BL21 (DE3) 
E.coli strain, with vectors containing T7 promoter. The gene coding for the protein of 
interest is inserted in a vector with T7 promoter, a purification tag such as e.g. 6xHis-tag, 
FLAG, or GST, and a protease cleavage site. A widely used expression system is the pET 
expression system, a variant of this is pNIC28-Bsa4 [9], which is used for ligation 
independent cloning (LIC)[10]. The empty vector contains a SacB fragment that is 
cleaved of when the gene of interest is cloned into the vector, and used for negative 
selection on agar plates. It also contains a gene for antibiotics resistance as positive 
selection. Colonies from the plates are inoculated to flasks with medium added with 
antibiotics, and grown to an OD600 typically in the range of 0.5-1 and then induced with 
IPTG. The induced cells are grown over night and then harvested and lysed for further 
purification of the protein. 
It is critical to have a pure and well folded protein sample for successful crystallization of 
proteins for structural studies. In order to obtain that, the cell lysate with the protein of 
interest undergoes several purification steps; first an initial extraction from the E.coli 
lysate, often using a purification tag, and then purification using more elaborate methods 
such as Size-Exclusion Chromatography (SEC), Ion-exchange chromatography or 
hydrophobic interaction chromatography. For structural applications, the affinity captor 
of the protein is often combined with SEC when the later also is a good test of protein 
homogeneity.   
Several purification tags can be used for protein purification, the His-tag is often used in 
purification from E.coli extracts as it provides good yields of proteins from high capacity 
resins [11] and does not affect the characteristics of the protein. The 6xHis-tag is attached 
with a protease cleavage site at the N- or C-terminal of the protein. The His-tag permits 
the protein to be purified by immobilized metal ion chromatography (IMAC) [12]. Metal 
ions like Ni2+ are immobilized on agarose resin packed in columns, and targets the 
histidines when the lysate is flowing through the column. To elute the His-tagged protein 
from the column a buffer containing high concentration of imidazole is added to the 
column (figure 2). The His-tag is usually cleaved off with TEV protease because its 
flexible nature might negatively affect crystal formation.  
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Figure 2. IMAC. The lysate is added to the column and the His-tagged protein will bind to Ni- beads. 
The flow through is then discarded while the column is washed with buffer to remove unbound E.coli 
proteins. Finally, the protein is eluted with high concentration of imidazole. 
IMAC is usually followed by size exclusion chromatography to separate the protein of 
interest from contaminants and misfolded species. It is a method extensively used for 
protein purification as well as a control of protein folding/homogeneity. The protein 
solution is ran over a column packed with porous beads. Smaller protein will pass 
through the pores and larger proteins will pass by the beads in the column allowing for 
separation on size (figure 3). 
 
Figure 3. A cartoon illustrating the theory behind size exclusion chromatography. Small proteins (in blue) 
will pass through the beads (in red) in the column, the large proteins (in green) will pass on the outside of 
the beads and flow faster through the column and elute earlier than the small ones. 
The area under the peak in the chromatogram is directly proportional to the amount of 
protein. A monodisperse peak is indicating good quality of the protein. If protein is not 
of sufficient quality after SEC, other purification approaches might be needed such as ion 
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exchange chromatography. However, a poor SEC profile might indicate that the protein, 
as produced in E. coli, is not in good shape and therefor, in practice, in this situation it is 
often worthwhile to test additional expression constructs of the protein and in other 
conditions.  
2.2 ISOTHERMAL TITRATION CALORIMETRY 
In mechanistic studies of proteins detailed measurements of interactions of the protein 
with physiological ligand such as a metabolite or a drug, or a small molecule are 
important. Isothermal titration calorimetry (ITC) is the most sophisticated method 
available to biochemists to study ligand interactions with proteins in vitro. The method 
measure the energy released or absorbed upon a physical interaction between two 
molecular components. The information acquired from an ITC experiment is enthalpy 
change, entropy change, binding affinity and stoichiometry. The ITC instrument has two 
cells, one reference cell supplied with constant power and a sample cell where power is 
supplied depending on the reaction that occurs (figure 4). When the ligand is titrated into 
the cell, the instrument detects the heat that is absorbed or released. It is done by 
measuring the changes in power to keep the sample cell and the reference cell in at same 
temperature, i.e. isothermal conditions.  
 
Figure 4. (A) Schematic picture of the instrument. (B)The ligand is stepwise titrated into the sample cell. 
(C)For every injection the heat needed to keep the sample cell isothermal is measured giving rise to a peak. 
The peaks are integrated to give a binding curve from which it is possible to calculate ΔH, N and KD. 
The heat change is proportional to the amount of ligand bound and the binding enthalpy 
[13]. Therefore it is important that the concentrations of macromolecule in the sample 
cell and the ligand in the syringe are accurately measured for correct calculations. The 
first injection typically results in a large endothermal or exothermal signal because almost 
all ligand is bound to the macromolecule. For each injection the signal will be reduced as 
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the binding sites get more saturated. A typical exothermal ITC curve is shown in figure 
4C. The reaction stoichiometry, N, and the dissociation constant is determined from the 
titration equivalence point.  
There are several other methods available for binding studies of protein-ligand 
interactions. For example surface plasmon resonance (SPR) where one component 
usually a protein is immobilized on a sensor surface and a ligand is flown over the 
surface. Binding events are measured by monitoring change in resonance angle for the 
immobilized component [14]. Another method is weak affinity chromatography (WAC), 
where one component is immobilized on resin and another in the mobile phase. The 
stronger binding the longer the mobile phase will stay in the column [15]. WAC is good 
method for screening drug ligand libraries as it allows loading many ligands in the same 
time [16]. The great advantage of ITC compared to other methods in measuring protein-
ligand interactions is that it is possible to measure very small heat effects and therefore 
large binding constants up to 108-109 M-1. In both SPR and WAC the protein needs to be 
immobilized which is not needed for ITC. That could interfere with the binding surface 
why ITC has an advantage over the other methods.  Disadvantage of ITC is that 
relatively high concentration of protein is needed and that there is challenging to measure 
the binding of weak ligands. 
2.3 ANALYTICAL GEL FILTRATION 
 
Figure 5. Analytical gel filtration with individual proteins shown in green and red, are eluting at different 
time points, when run together on the column they form a complex eluting with a shorter retention time 
and increased absorption height in blue. 
Size exclusion chromatography can be used to study the interaction between two or more 
proteins. When using small volumes only for analysis the method is called analytical gel 
filtration (AGF). The individual proteins are first run one by one on the column to 
determine the elution volume of each individual protein. Then the proteins are mixed 
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with each other and run on the column. If the proteins interact with each other they will 
elute as a single peak at a shorter retention time than the individual proteins and with an 
increased absorption height (figure 5). In addition to studies of protein interactions AGF 
is also a valuable strategy to screen the homogeneity of membrane proteins after 
solubilization in different detergents [17]. 
2.4 LIMITED PROTEOLYSIS 
Limited proteolysis is used to obtain a more stable truncated construct of a protein than 
an existing longer construct. It is often explored in structural biology to remove flexible 
regions to e.g. improve crystallization. A protease is used to cleave the peptide where 
flexible exposed regions will be cleaved off first. Therefore a more stable construct 
without flexible parts can generated. . The bands on SDS gels will show different stages 
where flexible parts are cleaved off. At the end there will be only one small band left, 
which is the most stable construct.  The bands from the gel can then be analyzed with 
mass spectrometry to obtain the exact construct of the protein. In an alternative 
approach, a protease can be added directly to the crystallization trials to transiently 
generate highly crystallizable truncated proteins [18]. 
2.5 THERMAL SHIFT ASSAYS 
Thermal shift assays (TSA) are used within many different methods like CD, fluorescence 
spectroscopy etc. in order to study stabilization of proteins upon ligand binding (figure 
6).  
 
Figure 6. The protein denatures and unfolds when heated, the melting temperature is defined when half of 
the protein is unfolded. Upon adding ligand, the melting temperature is shifted (blue curve).  
Circular dichroism (CD) spectroscopy can be used in many types of studies of chiral 
molecules but it is in the study of macromolecules like proteins it has been most useful. 
Circular dichroism (CD) is the difference in the absorption of left‐handed circularly 
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polarized light (L‐CPL) and right‐handed circular polarized light (R‐CPL). It occurs when 
a molecule contains one or more chiral chromophores (light‐absorbing groups). CD is 
particularly good in studying the secondary structure of a protein and is therefore greatly 
influenced by the 3-dimension structure of the protein. Each structure has its own CD 
signature, see figure 7 [19]. This can be explored for structural study of a protein by 
predicting secondary structure content. The method is also useful for measuring 
conformational changes, including unfolding, due to change in temperature, pH, salt, 
ligands or denaturants. It is possible to use CD to measure the stability of a protein by 
determining the melting temperature, Tm, upon temperature increase. This is done by 
choosing a wavelength where the protein gives a strong or specific signal (like 222 nm for 
α helices) and measuring only at that wavelength while heating the sample. The melting 
temperature is the temperature where half of the protein is denatured. 
 
Figure 7. A CD spectrum of secondary structure, α helix, β sheet, and random coil. 
Two frequently used assays in our lab is Differential Scanning Fluorometry (DSF) or 
thermofluor and differential static light scattering (DSLS), or stargazer [20]. In 
thermofluor the sample is mixed with a dye that binds to hydrophobic patches, when the 
protein is heated and unfolds the signal from the dye becomes stronger, the event is 
monitored with real time PCR. With DSLS the fact that proteins often precipitate after 
unfolding is explored and scattered light is used to measure the amount of aggregates 
formed. All these methods require recombinant pure protein, which sometimes could be 
problematic and expensive to produce. 
Until recently it has not been possible to apply TSA in complex mixtures such as cells or 
cell extracts. Our group recently published a method based on the thermal shift concept 
in a cellular format, called Cellular thermal shift assay (CETSA) [21].  This assay allows, 
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for the first time, to directly measure the binding of a drug to its target protein inside 
cells.  This can serve as a basis for understanding whether the cell is able to transport the 
compound across the cell membrane or if the compound needs modification/activation 
for protein binding. The CETSA approach also allows for studies of physiological 
interactions inside the cell and has the advantage that it can be directly applied to other 
complex samples such as tissues and excreted body fluids to measure biochemical events.  
2.5.1 Experimental procedure of CETSA 
In a CETSA experiment cells are cultured and then either intact cells or cell extracts are 
used for adding a ligand or as control experiments, without added ligand. The cells or cell 
extracts are then aliquoted into PCR-tubes and the different aliquots are heated in a 
temperature scale. If intact cells are used, they are lysed after the heating step by freeze 
thaw cycles. During the heating step the target protein denatures or precipitates at the 
higher temperatures and if the ligand is stabilizing the protein, it denatures and 
precipitates at a higher temperature than the protein without ligand. The precipitated 
proteins has to be separated from the remaining soluble folded protein. This is done by 
centrifugation or filtration. The supernatant is then loaded onto SDS-PAGE, followed by 
western blot. In the detection step an immunoassay such as a western blot could be used. 
The western blot signals for the target protein should be stronger at the lowest 
temperatures and then start to decrease as the temperature increases. Plotting the 
intensities of the western blot signals against temperature will give a melt curve. By 
normalizing the intensities it will be possible to read out the Tm, which is the temperature 
where half of the protein is denatured. 
The CETSA method is also applicable for dose response experiments, which is often 
used in drug discovery to measure how efficient a drug is in different settings. It is the 
same procedure as mentioned above for obtaining CETSA melting curves, but instead of 
having a temperature scale the compound is added to intact cells or cell extracts at 
different concentrations. All the samples are then heated at the same temperature, which 
derived from the melt curve by taking a temperature where a strong difference is between 
the sample with and without ligand. After heating, the cell extracts or cells are processed 
as for the melt curve experiments. The band intensities are here normalized and plotted 
against the ligand concentration to give an isothermal dose response fingerprint 
(ITDRFCETSA) curve. The concentration at half-saturation is not the exact affinity, but 
typically shifted slightly [22], but it is characteristic fingerprint which can be used to e.g. 
compare different cell types, compounds etc. [21, 23]. For a more high-throughput 
procedure, it is possible to use other detection methods like AlphaScreen® or mass 
spectrometry [23]. 
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Figure 8. Schematic illustration over CETSA melt curve and ITDRFCETSA procedure.[21] 
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3 STRUCTURAL BIOLOGY 
Structural biology is the study of the molecular structure of biological macromolecules, 
especially proteins and nucleic acids, their three-dimensional molecular structure, how 
they acquire the structures, and how the structure affects their mechanism of action. This 
subject is of great interest to biologists because macromolecules carry out most of the 
functions in cells, and by folding into specific three-dimensional shapes, they are able to 
perform these functions.  
There are several methods to study protein structures, the most popular is X-ray 
crystallography, but nuclear magnetic resonance (NMR) spectroscopy and electron 
microscopy (EM), either of 2-dimensional crystals or single particle reconstitutions, also 
play important, but partly complementary, roles. These mentioned methods can yield 
high-resolution structures of proteins but a complement to these methods for lower 
resolution studies in solution is small angle X-ray spectroscopy (SAXS).  
3.1 X-RAY CRYSTALLOGRAPHY 
Already in 1934, J.D. Bernal and Dorothy Hodgkin showed that proteins packed in 
crystals diffracted X-rays in a complex but regular patterns. These patterns contained the 
essential information needed to determine a protein’s structure. This could however not 
be accomplished until Max Perutz and colleagues compared different patterns containing 
different heavy-metal atoms. The first protein structure was solved by Kendrew et al in 
1958 and was myoglobin from sperm whale [24]. 
X-ray diffraction is a common physical phenomenon and occurs when a wave (of any 
nature) encounters an obstacle, which can be any material object. This results in bending 
of the wave around that object, also called scattering of waves.  X-rays are 
electromagnetic waves with a wavelength of around 1 Å (i.e. 10-10 m, 0.1 nm). Diffraction 
from atoms in a crystal are following Bragg’s law, the pattern produced gives information 
about the distance between the crystal planes. To collect a typical diffraction pattern from 
proteins, the beam of the x-rays should be monochromatic (only one wavelength), high 
intensity, and highly focused. While rotating the crystal in the beam diffraction images are 
collected. An example is shown in figure 9. Each diffraction spot corresponds to a point 
in the reciprocal lattice and represents a wave with an amplitude (F) and a relative phase 
() used in the process to generate the experimental electron density. The structure 
factors for the various points on the reciprocal lattice correspond to the Fourier 
transform of the electron density distribution within the unit cell of the crystal. The 
Fourier transform is reversible, which means one can go from electron density to 
reciprocal phase and back again. The problem with going from reciprocal space to 
electron density is the missing phase information required for the generation of the 
electron density, this is called the phase problem. 
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Figure 9. Diffraction pattern from a protein crystal. Each diffraction spots corresponds to point in the 
reciprocal lattice. 
The phase problem can be solved with several methods.  
The most straight forward is molecular replacement, which can be used in cases where 
there is an homologous structure, preferably with at least 35% sequence identity [25]. The 
known structure model is used as an initial model for phase generation after the rotation 
and translation problem has been solved, which allow the positioning of the molecule in 
the crystal lattice.   
Isomorphous replacement and Anomalous dispersion are both based on the present 
of a heavy atom in the protein that is scattering the X-rays in a different way than 
carbons, oxygen and nitrogen. For isomorphous replacement a diffraction pattern of the 
native protein crystal and a derivative is needed, for anomalous dispersion a diffraction 
pattern of the derivative is enough. For isomorphous replacement it is important that the 
heavy atom does not change the structure of the protein i.e. the unit cell has to be the 
same. For anomalous dispersion methods the measurements of the diffracted intensities 
have to be very accurate, to allow small differences between, so called, Friedel pairs to be 
derived which can be used to calculate the initial phase information.  
3.2 SAXS 
Small-angle X-ray scattering (SAXS) is used to study biological macromolecules in 
solution. SAXS provides information about the overall structure and structural transitions 
of native biological macromolecules in solutions at low resolution (1–2 nm). The 
experiment is more straightforward as compared to crystallography; there is no need for 
crystallization, isotopic labelling, or heavy atoms. The measurements are performed close 
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to the primary beam, hence the name “small-angle”. The sample solutions are exposed to 
monochromatic X-rays and the sample is scattering the waves, the solvent is measured 
separately to subtract the solvent scattering from the sample. The net intensity is used to 
extract the structural information, it is proportional to the scattering from a single particle 
averaged over all orientations. Using the precise scattering patterns recorded at 
synchrotrons, SAXS can reveal the shapes and weight of protein molecules and 
nanoparticles e.g., radius of gyration Rg, maximum diameter Dmax, volume of the 
hydrated particle Vp, and the molecular mass of the particle. Moreover, the low resolution 
macromolecular shape can be obtained ab initio (i.e., without information from other 
methods), and molecular models can be constructed using high resolution or homology 
models of individual domains or subunits.[26]. However, care has to be taken with 
generated structures when it sometimes is hard to distinguish that right structure model 
from false structure models. 
To process the data several programs are available, to create atomic models and fit the 
experimental scattering data. For example ATSAS is based on molecular dynamics, where 
structured regions can be maintained as rigid bodies, and flexible loops and termini are 
allowed to move, bond lengths are kept constant. Conformational sampling is followed 
by structure validation and a minimal ensemble search (MES), where the program will 
identify ensembles that together will be similar to the scattering curve. 
 
Figure 10. Scattering intensities and distance distribution functions of geometrical bodies. [27] 
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4 PROTEIN PHOSPHATASE 2A 
4.1 SERINE/THREONINE DE-/PHOSPHORYLATION 
Reversible phosphorylation and dephosphorylation events are essential for the regulation 
of a multitude of cellular functions [28, 29]. Protein phosphorylation was first introduced 
by Edmond Fischer and Edwin Krebs [30-32] when they could demonstrate the process 
of a protein transferring a phosphate group from ATP to phosphorylase b resulting in 
phosphorylase a. The converting protein was named phosphorylase kinase. Another 
protein performed the reverse conversion, dephosphorylation, that protein was named 
phosphorylase phosphatase[33].  
 
Figure 11. Kinases and phosphatases are working together by activating and deactivating proteins via 
phosphorylation and dephosphorylation respectively. 
The protein family that is responsible for transferring a phosphate from ATP to a protein 
is named protein kinases, and the family responsible for the opposite is called protein 
phosphatases (figure 11). In eukaryotic cells de-/phosphorylation mainly occurs on 
hydroxyls of serine, threonine and tyrosine residues of substrate proteins. The human 
genome contains only ≈30 protein Ser/Thr phosphatases (PSPs) in comparison to 428 
Ser/Thr kinases (PSKs). The reason for this difference is that holoenzymes of PSPs are 
generate by combinations of regulatory subunits interacting with a limited number of 
catalytic subunit, discussed further below.[8]. The PSPs are divided in three major groups: 
phosphoprotein phosphatases (PPPs), metal-dependent protein phosphatases (PPMs), 
and the aspartate-based phosphatases represented by FCP/SCP (TFIIF-associating 
component of RNA polymerase II CTD phosphatase/small CTD phosphatase)[8]. For 
several members of the PPP family, the catalytic subunit associates with a great variety of 
regulatory subunits. Representative members of the PPP family include protein 
phosphatase 1 (PP1), PP2A, PP2B (commonly known as calcineurin), PP4, PP5, PP6, 
and PP7. 
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4.2 CELLULAR ROLL OF PP2A 
The cell cycle is regulated in a complex system initiated by many different pathways such 
as e.g. MAPK and Wnt signaling. Protein phosphatase 2A (PP2A) participates in various 
pathways controlling metabolism, DNA replication, transcription, RNA splicing, 
translation, cell cycle progression, morphogenesis, development and transformation [34-
37]. Protein phosphatase 2A is regulating other proteins either negatively or positively by 
dephosphorylation. As an example, PP2A regulates so called pocket proteins, which 
negatively regulate the cell cycle by targeting transcription factor E2F. E2F then 
modulate the expression of genes involved in cell cycle progression. Pocket proteins 
consist of p107, p130 and pRb [38]. They are active in their hypophosphorylated state, 
and inhibited when they are phosphorylated by cyclin/CDK complexes [39]. Active 
pocket proteins bind to E2F inhibiting DNA synthesis (Figure 12). When pRB/p107 is 
phosphorylated, E2F gets released and expresses genes allowing entry to S phase [40]. 
Different cell stress signals activate PP2A to dephosphorylate pocket proteins leading to 
cell cycle arrest or apoptosis. For example oxidative stress induces an increase of Ca2+ 
intracellular levels activating PP2A, which leads to dephosphorylation of pRb [38].  
 
Figure 12. PP2A have several roles in the cell, one of them is to dephosphorylate pocket proteins (p107 
and pRb) when the cell is stressed from UV-radiation, ligands or hydrogen peroxide. The pocket proteins 
are stopping the cell to enter S phase by binding to E2F. 
Another substrate of PP2A is Cell Division Control 6 (Cdc6) protein, which contains 
three phosphorylation sites. Cdc6 is the gate keeper for the G1/S transition and is 
required for DNA replication [41]. When Cdc6 is dephosphorylated by PP2A PR70 it 
allows the cell to proceed from G1 to S phase initiating DNA replication. Interestingly 
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high levels of Ca2+ increases association of Cdc6 with the catalytic and scaffolding 
subunits of PP2A but does not affect the PR70/Cdc6 interaction [42]. 
Protein phosphatase 2A has been suggested to be a tumor suppressor [43] consistent 
with that okadaic acid, a potent tumor promoter, is strongly inhibiting PP2A. This was 
verified after Wang et al. found that the gene coding for the β isoform of A subunit was 
altered in 15 % of primary lung tumors, and 15 % of primary colon tumors [44]. Several 
mutations in both α and β isoforms have been found in diversely different cancer types 
[45]. In Aαisoform, four point mutations namely E64D, E64G, E393Q and R418W are 
found in cancer. In Aβ isoform, eight point mutations have been found in cancer patient, 
they are G8R, P65S, G90D, L101P, K343E, V448A, D504G, and V545A [46].  
4.3 THE HOLOENZYME OF PP2A 
Protein phosphatase 2A (PP2A) is a major Serine/Threonine phosphatase that together 
with Protein phosphatase 1 accounts for more than 90 % of all dephosphorylation 
processes in any given tissue or eukaryotic cell. Each holoenzyme consists of a common 
core formed by the scaffolding (A) and the catalytic (C) subunit (two isoforms each) and 
associates with a variable regulatory B-subunit to form a heterotrimeric complex (figure 
13). 
Figure 13. PP2A holoenzyme consists of three subunits, a scaffolding (PP2A-A), a catalytic (PP2A-C) 
and several regulatory subunits (PP2A-B) divided in three families. The B-subunits recognizes the 
substrate giving PP2A substrate specificity.  
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4.3.1 The scaffolding subunit 
PP2A-A, the scaffolding subunit, consists of 15 tandem HEAT (Huntingtin-Elongation-
A subunit TOR) repeats that formed an overall conformation similar of a hook [47]. 
Each HEAT repeat is formed by two antiparallel α-helices, with inter-helical loops that 
are highly conserved through evolution. Structural studies have shown that HEAT 
repeats 11-15 are involved in binding the catalytic subunit [48] while the ridges in HEAT 
repeats 1-8 are involved in binding the regulatory subunit [49, 50]. When binding to 
catalytic subunit, HEAT repeats 13-15 are moving 20-30 Å resulting in a drastic 
conformational change between repeat 12 and 13, this gives the scaffolding subunit a 
more horse-shoe like shape [48]. When forming the holoenzyme the N-terminal repeats 
of the scaffolding subunit are moving 50-60 Å, the changes and the flexibility in the 
scaffolding subunit may facilitate the phosphatase activity by moving the bound substrate 
protein on regulatory subunit, closer to the catalytic subunit. The scaffolding subunit 
exists in two different isoforms; α and β, they have 85% sequence identity but binds with 
remarkably different affinities to the regulatory and catalytic subunits [46]. β isoform is 
expressed in much lower levels than α isoform in the cell [51]. The β isoform also has 12 
extra amino acids in the N-terminal that does not exist in the α isoform, but the exact 
role of these residues is still uncertain.   
4.3.2 The Catalytic subunit 
PP2A-C, the catalytic subunit, exists in two different isoforms; α and β. Other 
phosphoprotein phosphatases (PPPs) share together with PP2A a conserved fold as well 
as the structure essential parts of the active site [8].  However catalytic subunits of other 
PPPs do not bind to the scaffolding subunit of PP2A. Structural analysis of the interface 
between the catalytic and scaffolding subunits shows that the amino acids in the catalytic 
subunit that are important for interaction are not the same in PP2A and other PPPs. (ref) 
The catalytic subunit of PP2A has a highly conserved carboxyl-terminal tail, with a 
TPDYFL motif. This is important for the holoenzyme assembly and in the selection of 
proper regulatory subunits. Post-translational modifications of the tail, including 
methylation of leucine and phosphorylation of tyrosine, are also adding further control of 
B regulatory subunit selection [52]. 
4.3.3 The Regulatory subunit 
There are four families of regulatory B-subunits with no homology between them. They 
have very different expression levels in different cell types and tissues. Examples of B-
subunits are: B/B55/PR55, B’/B56/PR61, B’’/PR72 and B’’’/Striatin/PR93 [53, 54]. 
Within the holoenzyme, the regulatory B-subunit controls the function of PP2A by 
mediating substrate specificity and modulating the catalytic activity. Crystal structures of 
PP2A holoenzymes with members of the regulatory B, B’ and recently B’’ subunit 
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families [41, 49, 50, 55, 56] have shed light on the overall enzyme architecture and gave 
initial ideas on how regulatory subunits might affect PP2A activity. 
The regulatory subunits from different families are not related in their structures and 
therefore show no sequence homology.  B/B55/PR55 forms a seven-bladed β-propeller; 
each blade is a WD40 repeat [57] (a repeat of 40 residues ending with a tryptophan and 
an aspartate residue) with four β-strands. At the top face of the propeller, there is a highly 
acidic groove; this groove is predicted to host the substrate-binding site. A key function 
of PP2A-B55 is to dephosphorylate the hyperphosphorylated Tau protein, preventing 
Tau to polymerize into neurofibrillary tangles in the brain, which is a process implicated 
in Alzheimer’s disease [58-60]. The bottom face of the β-propeller binds to the ridges of 
HEAT-repeat 3-7 in the scaffolding subunit, and an extended β-hairpin arm reaches 
down to interact with HEAT-repeat 1 and 2 (figure 13) [50] B/B55/PR55 makes few 
interactions with the catalytic subunit; the FYDL-motif was disordered in the crystal 
structure, indicating that methylation of this motif is not essential for holoenzyme 
assembly in this family. 
B’/B56/PR61 has a similar fold as the scaffolding subunit, consisting of eighteen α 
helices where sixteen of them are forming eight HEAT-like repeats. The protein has an 
elongated structure with an apparent curvature. The convex side contains a number of 
conserved residues forming interactions with HEAT-Repeat 2-8 of the scaffolding 
subunit [49]. The potential substrate-binding site is acidic and positioned on the concave 
surface of the regulatory subunit B’, close to the active site of the catalytic subunit [8]. 
B’’/PR70/PR72 had until recently an unknown structure. The only predicted structural 
elements were two EF-hands involved in Ca2+binding. Structure and interaction with the 
scaffolding subunit will be described further down. 
4.4 STABILITY STUDIES OF SCAFFOLDING SUBUNIT ALPHA AND BETA 
ISOFORM 
As mentioned above, many cancers show mutations of the scaffolding subunit of PP2A. 
It has also been demonstrated that these mutations affect the formation of the 
holoenzyme complex [61]. The stability of a protein can give information about the effect 
of the mutations.  To study the thermal stability of both the α and β isoform wild-type 
and mutant proteins, we performed a study where the PP2A scaffolding subunits were 
heated from 20 to 70 °C and measured with CD at a wavelength typical for α helices 
(figure 14). These experiments revealed that the β isoform is more than 10 °C less stable 
than the α isoform in spite of their high sequence similarity. We also showed that all 
cancer related mutations in β isoform are destabilizing the scaffolding subunit, except 
L101P and D504G that give a small stabilization of 1 °C. The later mutations are located 
at the interacting site of B and the C subunits, hence affecting the binding and not the 
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intrinsic stability. The most destabilizing mutant was K343E, which is situated between 
HEAT repeat 10 and 11 forming the hinge region between the two parts binding the B 
and C subunit respectively. For the α isoform none of the mutants was found to 
destabilize the scaffolding subunit. 
 
Figure 14. Melt curves of scaffolding subunit α and β isoform of wild-type and mutants. α 
isoform is significally more stable than β isoform. 
4.5 STRUCTURAL AND BIOCHEMICAL CHARACTERIZATION OF HUMAN 
PR70 IN ISOLATION AND IN COMPLEX WITH THE SCAFFOLDING 
SUBUNIT OF PROTEIN PHOSPHATASE 2A (PAPER I) 
4.5.1 Construct design 
No structure was known for the heterotrimeric complex of A/C/B’’ until recently [41]. 
The missing piece in the puzzle of PP2A had to be found. The catalytic subunit of PP2A 
was impossible to express in E.coli and in our hands, and only low levels could be 
produced in insect systems. Luckily, the A/B’’-complex was possible to produce and 
assemble without the C subunit, this is not possible for any other of the other studied B-
subunits. Several crystallization attempts of the full-length constructs of A and B’’/PR70 
in complex failed. Subunit A was able to crystallize by itself but together with B’’/PR70, 
there were no crystals. Full length B’’/PR70 didn’t crystallize by itself either. Instead we 
designed constructs that still had the predicted interacting regions but not the flexible 
regions of the A subunit, .It was known that HEAT-repeats in the N-terminus are 
involved in the interaction with the regulatory subunit, so by first deleting repeat 11-15 
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and subsequently one HEAT-repeat at a time from the carboxyl terminus, 10 new 
constructs were designed, where four allowed soluble protein to be produced. These 
were for HEAT repeats 1-7, 1-8, 1-9 and 1-10. These protein constructs were analyzed 
on analytical gel filtration (AGF) with full length B’’/PR70 to see which constructs were 
still able to form the complex. All except repeat 1-7 retained the complex forming 
abilities. The new constructs of Aα formed a complex with full length B’’ did 
unfortunately not crystallize either. 
A more stable B’’/PR70 construct without flexible regions could potentially help, to 
obtain this limited proteolysis was performed. Full length B’’/PR70 was mixed with 
chymotrypsin, and aliquots were taken at time points between 0 and 360 minute and 
studied by SDS-PAGE. Three different bands were identified on the gel. The bands were 
cut out from the gel and analyzed with mass spectrometry. Three new constructs were 
designed with construct boundary of 25-483, 130-575 and 130-483. Preceding these 
experiments, a construct of residues 105-575 already existed. The new constructs were 
run on AGF together with full length and HEAT 1-8 of A subunit, revealing that 
constructs 25-575 and 105-575 was making a nice complex. Unfortunately none of the 
complexes crystallized. Therefore, crystal screens for the different B’’/PR70 constructs 
alone was also set up. 
4.5.2 Crystallization and structure determination of PP2A PR70 
The core domain with residues 130-483 was the only construct yielding well diffracting 
crystals. No molecular model was available for phasing at that time, so the protein was 
cultured in minimal media with seleno-methionine to be used for anomalous dispersion 
experiments. Data were collected at the selenium edge at Diamond Light Source 
beamline I04, a tunable beam line with Pilatus detector. The phasing was done with 
single-wavelength anomalous dispersion (SAD), where differences in diffracting 
intensities of anomalous pairs, were used to identify selenium sites, and to calculate initial 
phase information. In total 10 selenium sites were found and the initial structure was built 
and subsequently refined using Phenix, with manual rebuilding in Coot in each cycle of 
the refinement.   
4.5.3 Overall structure of PR70 
The crystal structure of PR70 revealed an elongated protein with eight EF hands. The 
protein can be divided into two domains connected with a 12 residue long linker (figure 
15). Except for two EF-hands there was no previous structure predicted for PR70. A 
search on the amino acid level did not return any structure homologues. However a 
DALI search on the structure, returned a hit for the regulatory subunit of calcineurin 
(calcineurin B), each of the domains of PR70 have a similar fold as calcineurin B and was 
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therefore named Calcineurin B-like domains (CBLD). A CBLD consists of four EF 
hands, CBLD1: EF hands 1-4 and CBLD2: EF hands 5-8 
 
Figure 15. The overall crystal structure of PR70 core fragment. CBLD1 is shown in mint green and 
CBLD2 in magenta, the linker is shown in blue.  
The EF-hand is a helix-loop-helix motif (E-helix, EF-loop, F-helix), which often has the 
capacity to bind calcium. The EF-loop is twelve residues long and has a consensus 
sequence with aspartate residues in positions 1, 3, 5, glycines in positions 4, 6, and a 
glutamate in position 12 (table 1) [62, 63]. EF-hands tend to come in pairs forming a 
discrete domain; many come in two, four, six or eight EF-hands, like is seen in the PR70 
core domain. The two EF-hands in a pair interact with each other via small β-strains in 
the EF-loop (figure 16A). In agreement with previous observations, only two of the EF 
hands of PR70 are binding calcium [38, 41, 42]. These EF-hands correspond to EF5 and 
EF7 in the structure (figure 16B). These were previously referred to as EF1 and EF2 
respectively in the literature when it was not known that the structure contained more 
than two EF-hands.). The major differences between EF5 and EF7 is the aspartate and 
the glutamate respectively in position 12, and the lack of glycines in position 4 and 6 in 
EF5 (table 1). The substitution of the canonical glutamate for an aspartate in position 12 
usually leads to a more compact EF-hand as the shorter side chain has to reach further to 
interact with the Ca2+ ion [63-65]. However, in EF5, the aspartate does not interact 
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directly with the Ca2+ ion, but forms a single indirect interaction mediated by a water 
molecule. The structure thus agrees well with the suggestions that EF5 binds calcium 
with lower affinity than EF7 [41, 42]. All other EF-hands of PR70 are consistently 
missing the aspartates in position 1, 3 and 5 and therefore it is not surprising that none of 
these EF-hands are binding calcium.  
Table 1. Sequence of EF loops 5 and 7. EF loop consensus sequence is shown. 
Residues conforming to the consensus are highlighted in grey.  
Position 1 2 3 4 5 6 7 8 9 10 11 12 
Consensus D  D G D G  I    E 
EF5 D T D H D L L I D A E D 
EF7 D L D G D G A L S M F E 
 
 
Figure 16. A) Two adjacent EF-loops are interacting with each other via a small β strain. B) Structure 
of EF loops 5 (pale orange) and 7 (violet). Water molecules interacting with calcium are red. Side chains 
are omitted for residues not directly involved in calcium binding (except for Asp-338). 
4.5.4 Binding of Ca2+ to PR70  
The crystal structure of PP2A PR70 revealed two Ca2+ ions bound to two EF-hands. 
This had previously been described as a unique feature for the B’’-regulatory subunit 
family [66]. To further investigate the role of calcium we used a thermal shift assay to 
study binding of Ca2+ to PR70. Thermal shift assays were measured using circular 
dichroism of PR70 (residues 105-575) with different concentrations of calcium. When 50 
µM calcium was added, there was a clear shift of Tm, from 29°C to 41°C (figure 17). 
Overloading PR70 with calcium (500 µM) a second shift could be seen. Plotting the Tm 
against calcium concentration (figure 17B) shows a two-step sigmoidal binding-curve 
suggesting two different binding events of calcium, one low affinity binding site and one 
high affinity binding site. This is in accordance with the structure of EF5 and EF7 were 
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EF5 was suggested to have lower affinity to calcium than EF7. The low affinity binding 
site, might be involved in regulation of PP2A binding to its substrates and to the activity 
[38] in response to changes in calcium concentration in the cell at certain signaling events. 
This is in agreement with data published from Magenta et al. [38] who showed that that 
PR70/PP2A activity increases with Ca2+ concentration, and if EF7 is mutated and it 
cannot bind calcium and activity is lost. To examine whether calcium was required to 
form the complex between the scaffolding subunit and regulatory subunit, size-exclusion 
chromatography was used, showing that calcium did not have a significant impact on this 
interaction.  
 
Figure 17. Calcium dependent thermal stability of PR70. A) Representative thermal unfolding curves of the 
PR70 construct (residues 105–575) are shown in the presence of the different Ca2+ concentrations. B) 
Ca2+-dependence of thermal unfolding suggests a low and high affinity Ca2+ binding site. 
4.5.5 A- and B’’-subunit interact with high affinity 
A specific feature for the B’’ regulatory subunit is that they can form a complex with the 
A subunit in the absence of the catalytic subunit. This does not appear to be the case for 
other B family members. To study this interaction and map the interaction surfaces of 
the scaffolding and regulatory subunit, different constructs of A and B’’ were analyzed 
with analytical gel filtration (AGF). To be able to detect binding on AGF the affinity has 
to be quite high, typically in the nM range, so that the complex does not dissociate on the 
column. AGF showed that HEAT repeat 1-8 of A was enough to bind to B’’/PR70, and 
that constructs with residues 25-575 and 105-575 of B’’/PR70 was binding to HEAT 
repeats 1-8 of A subunit.  
To further investigate the binding, isothermal titration calorimetry (ITC) was used to 
measure the affinity, dissociation constants and change in enthalpy of some constructs 
(Table 2). In agreement with AGF data, ITC results confirmed that PR70 and the Aα 
subunit interact with each other with high affinity. The parts of the two subunits that are 
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important for the binding are residues 105-575 of PR70 and HEAT-repeats 1-8 for Aα, 
because the interaction is in the nanomolar range, and there is no change in affinity 
comparing full length constructs with the shorter ones. When truncating PR70 further 
from the N-terminal by deleting the first 129 residues from the expression construct, the 
affinity dropped three orders of magnitude. The results indicate that residues 105-129 are 
important for the binding and belong to the interaction surface. What is also revealed 
with ITC is that the crystallized construct (PR70 130-483) was also binding to Aα with 
only very low affinity, which was probably the reason why the complex did not 
crystallize.  To examine whether the C-terminus of PR70 was important for forming a 
complex with Aα,a construct with only residues 484-575 was designed for the test, no 
binding could be detected. The conclusion we can draw from the ITC measurements is 
that residues from 105 to 129 of PR70 definitely belong to the binding surface and that 
probably some more residues C-terminal of residue 130 also contribute the binding 
surface. 
Table 2. ITC derived binding affinities of B’’-constructs to A-subunits 
B’’-subunit (residues) A-subunit Na KD (M) ∆H (kcal/mole) 
PR70 (25-575) A α (HEAT1-15) 0.84  0.02 0.112  0.006 -22.6  0.1 
PR70 (105-575) A α (HEAT1-15) 0.85  0.03 0.045  0.008 -19.7  0.2 
PR70 (130-575) A α (HEAT1-15)  > 100  
PR70 (130-483) A α (HEAT1-15)  > 100  
PR70 (484-575) A α (HEAT1-15)  NB  
PR70 (25-575) A α (HEAT1-8) 0.93  0.02 0.223  0.021 -19.1  0.4 
PR70 (105-575) A α (HEAT1-8) 0.99  0.01 0.158  0.022 -20.3  0.2 
 
4.5.6 And B’’- complex with SAXS 
Because crystallization attempts of the A-B’’–complex was not successful, the structure 
of the complex was determined at low-resolution with Small Angle X-ray Scattering 
(SAXS) instead. SAXS studies have the advantage that they are made in solution, so not 
crystals are needed. Potentially some of the large-scale dynamics of the protein can be 
monitored, when there are no crystal contacts limiting motions.  
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With SAXS a calculated mass of a protein that is in accordance with the size of the 
protein is retrieved. If the calculated mass is much higher than the real mass it gives an 
indication that the protein is inhomogeneous and potentially partly aggregated. The 
calculated mass for the A-subunit was 62.5 kDa, which is within the error range from the 
real molecular weight of 65.3 kDa. The experimental SAXS data of the A-subunit was 
compared with known structures of A-subunit alone and in complex with the 
holoenzyme with C, A and PR70(120-478), a homolog of PR72, which was published 
during the progress of our study was published [41], This gave best fit to the individual 
A-subunit and worst fit to the A-subunit in the complex, showing that the A-subunit is 
flexible and can have different conformations depending on what it is scaffolding. The 
comparison of the different holoenzyme crystal structures (3dw8.pdb[50], 4i5l.pdb[41]) 
with the obtained SAXS data also showed that the fit was not perfect, indicating that the 
crystal structures do not reflect all the conformations the A-subunit can form in solution. 
It was confirmed that the most flexible part of A-subunit is between HEAT repeat 10 
and 11, which is the linker between the HEAT repeats binding to regulatory subunit and 
catalytic subunit. The A-B’’complex with SAXS, PR70 (130-575) was subsequently 
modelled into the structure of holoenzyme with PR70 [41] suggesting that in the complex 
between the A- and PR70 subunits, the 15 HEAT repeats are still mobile and that the 
PR70 might be flexible  
 
Figure 18. Cartoon depictions of A-subunit models (green) and AB’’ complex models (green/blue) most 
consistent with the experimental SAXS data. A-subunit models were taken from representative pdbs. 
AB’’ complex models (blue) were based on the published complex structure 4i5l with the A-subunit of 
4i5l being replaced with A-subunits from other pdbs. The C-terminus (dark blue) was modeled using 
BilboMD 
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5 BIOCHEMICAL PROFILING OF P53 
5.1 P53 
p53 is a tumor suppressor protein which regulates the cell cycle. It is the most commonly 
mutated gene identified in human cancers, with 50% of the cancers having a mutation in 
p53. In response to DNA damage, cell stress and some oncogenic proteins, p53 level 
rises and induces cell cycle arrest or apoptosis. p53 is acting as a transcription factor [67] 
to regulate the expression of several different genes. In addition to directly regulate the 
cell cycle and apoptosis it is implied in cellular process such as metabolic stress sensing, 
genomic instability, angiogenesis etc. [68]. 
   
Figure 19. p53 pathway. Due to DNA damage, cell stress, oncogenic proteins etc. signal mediators are 
activated leading to Mdm2 dissociation from p53, activating p53. p53 binds to a response element (RE) 
on a target genes that gets transcribed leading to a response like cell cycle arrest, senescence, apoptosis or 
DNA repair. 
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5.1.1 DNA-binding  
p53 is a DNA-binding protein. The DNA-binding core domain of p53 consists of 
residues 94-292 that forms an immunoglobulin-like β-sandwich fold and a loop-sheet-
helix motif together with two large loops (L2 and L3) [69].The DNA-binding region is 
stabilized by a Zn ion. p53 binds to a consensus binding site on the DNA of the 
regulated gene. El-Deiry et al. conducted a precise mapping of the binding sequence 
which revealed a site with internal symmetry, consisting of two copies of a 10 base-pair 
motif 5’-RRRC(A/T)(T/A)GYYY-3’ (where R=G and A, and Y=C and T) separated by 
0-13 base pairs [70]. The consensus region could be shifted in some p53 target genes; an 
R gets replaced by a Y and vice versa. Each 10 base-pair motif is called a half-site and the 
whole binding sequence is called a response element (RE). p53 binds to DNA as a 
tetramer; two core domains are forming a dimer by binding on each side of a half-site on 
the DNA double helix, making intermolecular interactions with each other; core-domain 
to core-domain. The tetramer is then formed as a dimer of dimers. The L3 loop makes 
interactions with minor groove of DNA backbone via Arg248 in a direct or water-
mediated contact and where the Gly245 in the L3 hairpin is essential for the shape of the 
loop. Residues Ser241 and Arg273 make direct contact with the phosphate backbone of 
DNA. Arg280 makes a direct contact via two hydrogen bonds to the highly conserved 
guanine base at position seven in the half-site. Lys120, Ala276 and Cys277 make direct 
contacts with the major groove of each half-site [71] (figure 20). The carboxyl-terminal of 
p53 also has ability to bind non-specific DNA in unstressed cells, and helps rapid 
transactivation of p21 [72]. 
Figure 20. Model p53 core domain binding to DNA. The binding site is rich in 
basic amino acids. The six most frequently mutated residues are shown in green. 
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5.1.2 p53 as a tumor suppressor 
p53 was first found as a cellular partner of SV40 Large Tumor Antigen, a tumor-virus 
oncogene [73, 74]. A series of studies after the first finding suggested that p53 was 
involved in the tumorigenesis and viral replication by interacting with viral proteins from 
Adenovirus [75], human Papillomavirus [76, 77] and upregulated by T antigen from SV40 
[78]. p53 levels are negatively regulated by Mdm2, it is physically blocking the 
transactivation domain, inhibiting apoptosis and cell cycle arrest [79]. By disrupting 
Mdm2’s ability to bind to p53 by posttranslational modifications like phosphorylation, 
p53 gets stabilized and activated [80]. After activation, p53 is binding to the response 
element on the target genes which leads to activation or suppression of the target gene 
(Figure 20). Some of the target genes that lead to apoptosis are bax, puma, noxa, and 
apaf-1 [81]. p53 activation and regulation of target genes does not always leads to 
apoptosis, cell cycle arrest is another outcome. p21, an inhibitor of cyclin-dependent 
kinases (CDKs) is activated by p53. CDKs are regulating the cell cycle G1-to-S, and G2-
to-mitosis steps, hence the inhibition of the CDKs will lead to cell cycle arrest [68]. p53 is 
not just a tumor suppressor by initiating apoptosis and cell cycle arrest, it is also activating 
senescence. It is an irreversible cell cycle arrest, where the cells are unable to replicate 
DNA. One protein regulated by p53 that leads to senescence is plasminogen activator 
inhibitor 1 (PAI-1) [82] and another is p21 [83]. All three outcomes of the p53 
transcriptional program can lead to the suppression of tumors. Apart from apoptosis and 
senescence, p53 is also capable of contributing to cell survival by targeting proteins that 
function as apoptosis inhibitors, such as decoy death receptors DcR1 and DcR2 [84]. The 
effect of p53 activation is decided by many different factors, for example the type of 
tissue, the nature of the stress signal, and the environment of the cell. The decision  
whether p53 should act as cell killer or savior could also be dependent on the extent of 
damage or the duration of stress [85]. Small damages lead to repair of the DNA in 
contrast to bigger damages that lead to cell death [86]. 
5.1.3 p53 in cancer 
Unlike other tumor suppressor genes that are not expressed in cancer cells, p53 is 
expressed in cancer cells as the full length protein, but with missense mutations resulting 
in single amino acid substitutions. Interestingly mutant p53 is often expressed in higher 
levels than the wild-type [87]. Mutant p53 loses some of its ability to bind to DNA but 
also tends to gain oncogenic functions, such as interference with wild-type p53-
independent apoptosis[88]. The DNA-binding domain of the p53 protein is a “hot spot” 
for mutation, as the majority of tumor-associated mutations in p53 occur within this 
region [89]. Six residues; Arg175, Gly245, Arg248, Arg249, Arg273 and Arg282 in the 
DNA binding domain are frequently mutated. (green in figure 20). The DNA-binding 
domain is rich in basic residues and mutations on any of the arginine, leading to loss of 
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DNA binding. Arg273 plays a crucial role in DNA binding by docking p53 to the DNA 
backbone, mutations of this residue are abundant in human cancer, and leads to dramatic 
loss of DNA binding affinity [90]. Gly245 is important for the stabilization and folding of 
p53 as it is located in the L3 loop.  
5.2 CETSA STUDIES OF DNA-BINDING TO P53 (PAPER II) 
As described above, p53 is binding to DNA at a genes response element (RE). In 
principle there are many methods for evaluating p53 DNA binding, such as 
electrophoretic mobility shift assay (EMSA) [91], DNA foot printing [92], ELISA-based 
techniques with biotinylated REs to capture p53-DNA complexes on streptavidin plates 
[93], microsphere assay of protein-DNA binding (MAPD) [94] or a multiplex in vitro 
binding assay quantified with real-time PCR [95]. Other methods used for p53-DNA 
binding assays are surface plasmon resonance (SPR) and fluorescence anisotropy. All 
these methods however, require either recombinant p53 or in vitro overexpressed p53. We 
wanted to study p53 in cancer cell lines under a more natural environment without the 
need of cloning and overexpressing p53. To accomplish this CETSA was used on cancer 
cell extracts. When oligonucleotides containing REs were added to cell extracts of the 
cancer cell line (A549) harboring wild-type p53 and one harboring R273H mutant p53 
(HT-29), very significant shifts in the Tm for the wild-type p53 were seen but no 
significant shifts were seen for the mutant p53, suggesting that it is indeed possible to 
monitor DNA binding events with CETSA in cell extracts (paper II) [22]. 
5.3 PROFILING OF P53-DNA BINDING (PAPER III) 
We wanted to make a proof-of-principle study for the potential to use CETSA to track 
differences between different mutant and wild-type p53s, and how they bind to REs of 
different genes. The initial question asked was: does some mutant p53 lose their ability to 
bind DNA completely or just with decreased affinity and whether some mutants still bind 
to some gene REs but not others? The profiling study would potentially give a better 
view how p53 is regulating genes where p53’s ability to bind to different REs could shed 
light on which p53 regulated processes important for the progression of cancer are 
activated.  
5.3.1 Method 
The lung carcinoma cell line H1299, a p53 null cell line transfected with wild-type or 
mutant p53 was kindly provided by David Lane. The cell lines have the same genetic 
background and the only thing altered is the form of transfected p53. This gives 
possibility to study only the changes on p53 function so that the DNA binding ability is 
not affected by other factors. Wild-type and four different p53 mutants, G245S, R248Q, 
R273C and R273H, were used for the CETSA experiments. Cell extracts from the 
different cells harboring the p53 variants were incubated with five different 
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oligonucleotides, of which four contain the response element: p21, PUMA, GADD45 
and ConA, and one without the response element as a control: WRNC, as shown in table 
3. 
Table 3. Oligonucleotide sequences corresponding to REs for genes in the study 
Oligo name Oligonucleotide Sequence 
ConA CTTTCTGGCCATCATGGGCATGTCCGGGCATGTCCAGCTCTGGCATAGAA 
p21 CTTTCTGGCCATCATGAACATGTCCCAACATGTTGAGCTCTGGCATAGAA 
PUMA CTTTCTGGCCATCATCTGCAAGTCCTGACTTGTCCAGCTCTGGCATAGAA 
GADD45 CTTTCTGGCCATCATGAACATGTCTAAGCATGCTGAGCTCTGGCATAGAA 
WRNC CTTTCTGGCCATCATGAAAGGTGGATTTAGGTGGAAGCTCTGGCATAGAA 
5.3.2 Results 
Initially we wanted to investigate the differences in p53 mutants’ stability as well as their 
ability to bind to DNA for different p53 target genes. The results indicate that there were 
no major differences in the Tm of the different mutants in cell extracts although G245S 
might be somewhat less stable than the wild-type (figure 21). This later would be in 
accordance with previous studies, where it was shown that G245S destabilizes the DNA 
binding core-domain of p53 [96]. The results also demonstrated that not all mutant p53 
were interacting to the same extent with different oligonucleotides. For example, PUMA 
show little stabilization for R273H but binds all other mutants. The results also 
demonstrated that the mutation in residue 273 to a histidine and cysteine results in 
somewhat different DNA binding profiles, presumably due to the different size and 
polarity of these residues. 
The DNA binding capabilities of two different cell lines harboring wild-type p53 was 
studied to see if there were any differences in how wild-type p53 behaves in cancer cells. 
These were also compared with the different p53 mutants. Since p53 is an important 
tumor suppressor and is mutated in half of all cancers, it is possible that even wild-type 
p53 in some cancer cells might change their ability to bind DNA, for example due to 
other regulating proteins activating or deactivating p53. 
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Figure. 21. Stability measurements of mutant and wild-type p53. Heat induced unfolding, detected with western 
blot. The top shows the melt curves of the mutants and wild-type p53. The diagram is illustrating the Tm. 
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To test this hypothesis the breast cancer cell line, MCF7, with wild-type p53 and H1299 
wild-type was used. The stabilization of p53 in MCF7 appears dampened as compared to 
H1299 where p53 is transfected into the cell (figure 21). This suggests that there might be 
an overall difference in DNA binding capabilities between different wild-type p53 
harboring cell lines but no significant difference between how they bind to the different 
oligonucleotides. p53 binds unspecifically to DNA at the C-terminal [97] therefore we 
also investigated whether it was the unspecific binding of oligonucleotides that was 
measured in the CETSA experiments. The results showed a slight stabilization using 
WRNC, an oligonucleotide without an RE, but not in the same extent as with the 
oligonucleotides containing the RE. 
5.4 CETSA FOR GENERATION OF CANCER BIOMARKERS 
Understanding how wild-type and mutant p53 binds to its target genes could be helpful 
in restoring the function of mutant p53 in cancer cells. Several drugs have been 
developed that can, restore the biological function of p53 [98]), inhibit Mdm2´s ability to 
bind to p53 [99] or stabilize p53 mutants [100]. Using CETSA coupled with a high 
throughput detection method like AlphaScreen® it is possible to rapidly screen for drug 
candidates in compound libraries [23].  
In Paper II, CETSA was implemented to study interactions of drugs at the proteome 
level which has a number of important applications. For example, it is often important 
that drug candidates are specific for the intended target and does not hit other protein, 
when such off-target effects can lead to adverse effects. CETSA combined with 
quantitative mass spectrometry (MS) for thermal profiling of drug targets is in Paper II 
used for finding off-targets of kinase drugs. When using MS as a detection method for 
CETSA it is possible to screen a cellular proteome comprising over 7000 proteins for 
interactions with the drug. Cells are cultured with and without added drug, or cell extract 
re generated as above, and then heated at different temperatures, for each temperature a 
sample is taken and the soluble fraction is quantified by mass spectrometry to yield melt 
curves (Figure 22). From the melt curves, targets that are binding the drug could be 
identified.  
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Figure 23. Heated samples are analyzed by LC-MS/MS. The soluble fraction decreases with higher 
temperatures. The intensities is plotted against temperature to yield melt curves [22]. 
In this work the heme biosynthesis enzyme ferrochelatase (FECH) was identified to be 
an off-target of the drug vemurafenib that is developed as a kinase inhibitor targeting 
BRAF [22]. The work also shows that functional changes in the cell downstream if the 
drug target BCR-ABL can be directly monitored. This implicates that MS-CETSA could 
be an important method to identify markers for drug efficacy and toxicity. In the future 
MS-CETSA could also be used as a method to find cancer biomarkers based on the 
thermal melting of the proteome that can be used in diagnosis or prognosis. 
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